Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Head & Neck 2Gynecologic 2Gastrointestinal 2Breast 2Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Uterine Cervical Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Stomach Neoplasms 5Triple Negative Breast Neoplasms 4Carcinoma, Renal Cell 4Advanced Solid Tumors 4Urinary Bladder Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Melanoma 3Lung Neoplasms 3Solid Tumor 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Kidney Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Breast Neoplasms 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urothelial Bladder Carcinoma 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Solid Tumors 1Solid Tumor, Unspecified, Adult 1Sarcoma 1

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 81Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25Cystoscopy 24enfortumab vedotin 23Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × zimberelimab × Clear all
NCT05891171 2026-03-31

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06528483 2024-07-30

preSAVE

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Not yet recruiting
63 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03629756 2024-05-24

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences, Inc.

Phase 1 Completed
48 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡